TW200942819A - Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB) - Google Patents

Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)

Info

Publication number
TW200942819A
TW200942819A TW098108600A TW98108600A TW200942819A TW 200942819 A TW200942819 A TW 200942819A TW 098108600 A TW098108600 A TW 098108600A TW 98108600 A TW98108600 A TW 98108600A TW 200942819 A TW200942819 A TW 200942819A
Authority
TW
Taiwan
Prior art keywords
alzheimer
disease
methods
specific
cells
Prior art date
Application number
TW098108600A
Other languages
English (en)
Inventor
Tapan Kumar Khan
Daniel L Alkon
Original Assignee
Brni Neurosciences Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/078,857 external-priority patent/US20080221042A1/en
Application filed by Brni Neurosciences Inst filed Critical Brni Neurosciences Inst
Publication of TW200942819A publication Critical patent/TW200942819A/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW098108600A 2008-04-07 2009-03-17 Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB) TW200942819A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/078,857 US20080221042A1 (en) 2005-10-11 2008-04-07 Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB)

Publications (1)

Publication Number Publication Date
TW200942819A true TW200942819A (en) 2009-10-16

Family

ID=41037627

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098108600A TW200942819A (en) 2008-04-07 2009-03-17 Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)

Country Status (9)

Country Link
EP (1) EP2263090A1 (zh)
JP (1) JP2011516883A (zh)
KR (1) KR20100132997A (zh)
AU (1) AU2009234405A1 (zh)
BR (1) BRPI0911073A2 (zh)
CA (1) CA2720621A1 (zh)
IL (1) IL208296A0 (zh)
TW (1) TW200942819A (zh)
WO (1) WO2009126232A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103495A1 (en) * 2014-01-03 2015-07-09 Blanchette Rockefeller Neurosciences Institute Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease
EP3600027A4 (en) 2017-03-31 2020-12-23 Neurodiagnostics LLC LYMPHOCYTE-BASED MORPHOMETRIC TEST FOR ALZHEIMER'S MORBUS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043998A1 (en) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio

Also Published As

Publication number Publication date
BRPI0911073A2 (pt) 2019-09-24
WO2009126232A1 (en) 2009-10-15
AU2009234405A1 (en) 2009-10-15
CA2720621A1 (en) 2009-10-15
EP2263090A1 (en) 2010-12-22
KR20100132997A (ko) 2010-12-20
JP2011516883A (ja) 2011-05-26
IL208296A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
TW200801515A (en) Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio- alzheimer's disease-specific molecular biomarkers (ADSMB)
WO2007047029A3 (en) Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
EP3540442A1 (en) Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof
Jorge et al. Statistical Model to Analyze Quantitative Proteomics Data Obtained by 18O/16O Labeling and Linear Ion Trap Mass Spectrometry: Application to the Study of Vascular Endothelial Growth Factor-induced Angiogenesis in Endothelial Cells* S
JP5878875B2 (ja) アルツハイマー病の診断法
US20090011452A1 (en) Method of Prognosis of Mental Diseases, E.G. Autism and Cerebral Palsy
EP3015865A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
RU2011150279A (ru) Фосфодиэстераза 4d7 как маркер рака предстательной железы
ATE536553T1 (de) Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse
EP3088899B1 (en) Biomarkers for psychiatric diseases including cognitive impairment and methods for detecting psychiatric diseases including cognitive impairment using the biomarkers
JP2015105951A (ja) 血液由来の癌診断用ペプチドマーカー及びそれを用いた癌診断方法
KR20120125157A (ko) 렉틴을 이용한 암 진단 방법
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
JP2024096748A (ja) アルファ－シヌクレイン病のアッセイ、方法、及び治療
US20020006627A1 (en) Method for diagnosis of Alzheimer's disease
Yang et al. An alpha‐synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression
US20140018299A1 (en) Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury
RU2011150291A (ru) Фосфодиэстераза-9а в качестве маркера злокачественной опухоли предстательной железы
TW200942819A (en) Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)
CN109073661B (zh) 用于神经学疾病的诊断的测定法
KR100925147B1 (ko) 폐암 진단용 마커
CN103983787A (zh) 作为神经退行性疾病诊断/预后指示物的谷氨酰胺酰环化酶
WO2012175674A1 (en) Diagnosis and/or prognosis of a neurodegenerative disease
KR101219516B1 (ko) 암 진단용 펩티드 마커 및 이를 이용한 암 진단방법
KR102254053B1 (ko) 인지기능 정상군 또는 경도 인지장애에서 아밀로이드 베타의 뇌 침착 검출용 혈액 바이오 마커